BioXcel Therapeutics (BTAI) PT Raised to $122 at Guggenheim
Tweet Send to a Friend
Guggenheim analyst Yatin Suneja raised the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $122.00 (from $101.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
